Lisata Therapeutics マネジメント

マネジメント基準チェック /34

Lisata Therapeuticsの CEO はDave Mazzoで、 Jan2015年に任命され、の在任期間は 9.83年です。の年間総報酬は$ 1.41Mで、 48%給与と52%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.26%を直接所有しており、その価値は$ 297.61K 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と9年です。

主要情報

Dave Mazzo

最高経営責任者

US$1.4m

報酬総額

CEO給与比率	48.0%
CEO在任期間	9.8yrs
CEOの所有権	1.3%
経営陣の平均在職期間	4.1yrs
取締役会の平均在任期間	9yrs

経営陣の近況

Recent updates

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Jul 15

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Mar 22

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Sep 15

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Sep 14

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Aug 04

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

May 02

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Jan 05

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

May 09

Caladrius suspends CLBS119 COVID-19 study

Dec 14

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Nov 30

CEO報酬分析

Lisata Therapeutics の収益と比較して、Dave Mazzo の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$1m	US$676k	-US$21m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$56m
Dec 31 2022	US$2m	US$650k	-US$54m
Sep 30 2022	n/a	n/a	-US$55m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$631k	-US$27m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$613k	-US$8m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$7m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$2m	US$597k	-US$19m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$2m	US$594k	-US$16m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$14m
Dec 31 2017	US$1m	US$577k	-US$16m

報酬と市場: Daveの総報酬 ($USD 1.41M ) は、 US市場 ($USD 650.80K ) の同規模の企業の平均を上回っています。

報酬と収益: Daveの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dave Mazzo (67 yo)

9.8yrs

在職期間

US$1,408,382

報酬

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph D., served as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020 until February 29,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David Mazzo	President	9.8yrs	US$1.41m	1.26% $ 297.6k
Kristen Buck	Executive VP of R&D and Chief Medical Officer	3.2yrs	US$969.82k	0.75% $ 178.2k
James Nisco	Senior VP of Finance	3.7yrs	データなし	0.042% $ 9.9k
Tariq Imam	Vice President of Business Development & Operations and Corporate Counsel	1.8yrs	データなし	データなし
Gregory Berkin	Chief Information & Data Protection Officer	4.1yrs	データなし	データなし
John Menditto	Vice President of Investor Relations & Corporate Communications	6.9yrs	データなし	データなし
Gail Holler	Vice President of Human Resources	5.8yrs	データなし	データなし
William Sietsema	Vice President of Global Regulatory Affairs	no data	US$400.18k	データなし

4.1yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: LSTAの経営陣は経験豊富であると考えられます ( 4.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David Mazzo	President	9.8yrs	US$1.41m	1.26% $ 297.6k
Steven Klosk	Independent Director	10.3yrs	US$120.00k	0.0052% $ 1.2k
Gregory Brown	Independent Chairman of the Board	8.1yrs	US$149.50k	0.0033% $ 785.5
Heidi Henson	Independent Director	2.2yrs	US$124.00k	0% $ 0
Gerald Nepom	Member of Type 1 Diabetes Scientific Advisory Board	no data	データなし	データなし
Robert Negrin	Immune Modulation Program Advisor	no data	データなし	データなし
Robert Korngold	Immune Modulation Program Advisor	no data	データなし	データなし
David Pearce	Member of Type 1 Diabetes Scientific Advisory Board	no data	データなし	データなし
David Horwitz	Immune Modulation Program Advisor	no data	データなし	データなし
David Peritt	Immune Modulation Program Advisor	no data	データなし	データなし
Noel Warner	Immune Modulation Program Advisor	no data	データなし	データなし
Kevan Herold	Member of Type 1 Diabetes Scientific Advisory Board	no data	データなし	データなし

9.0yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: LSTAの取締役会は経験豊富であると考えられます ( 9年の平均在任期間)。

Lisata Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Less than half of directors are independent

Less than half of directors are independent

Insufficient new directors

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

Recent updates

Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Deliver On Growth Plans?

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius rallies on approval of merger, name change to Lisata Therapeutics

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences GAAP EPS of -$0.11 beats by $0.01

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

We Think Caladrius Biosciences (NASDAQ:CLBS) Needs To Drive Business Growth Carefully

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Price target decreased to US$8.00

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

We're Keeping An Eye On Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Rate

Price target decreased to US$9.00

Consensus forecasts updated

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Price target decreased to US$8.67

Companies Like Caladrius Biosciences (NASDAQ:CLBS) Are In A Position To Invest In Growth

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Analysts update estimates

Price target lowered to US$8.50

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

New 90-day high: US$2.89

Caladrius Biosciences, Inc. Treats First Patient in the Phase 2B Freedom Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Caladrius suspends CLBS119 COVID-19 study

Here's Why We're Not Too Worried About Caladrius Biosciences' (NASDAQ:CLBS) Cash Burn Situation

Price target raised to US$12.75

Caladrius Biosciences, Inc. Announces Executive Changes

New 90-day low: US$1.47

Caladrius Biosciences, Inc. Appoints Anne Whitaker to Board of Directors

Caladrius Biosciences, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$1.59

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

Insider recently bought US$100k worth of stock

New 90-day low - US$1.71

Caladrius Biosciences, Inc. to Report Q2, 2020 Results on Aug 13, 2020

CEO報酬分析

CEO（最高経営責任者

マネジメント基準チェック /34